 |
 |
 |
|||||||||
 |
 |
 |
|||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||
Subscribe
|
Companies in the News
|
||||||||
|
Atlanta Sports Marketing Company Partners with Swiss Firm in China
Helios will be the exclusive marketing and consulting partner in China of Infront Sports & Media and will initially help Infront market the fast-growing Chinese Basketball Association to potential sponsors. The league has 16 teams in 14 cities and drew more than a million spectators during the 2007-2008 season. Both companies already have offices in Beijing and high-profile clients throughout the country. Infront handles marketing initiatives for the CBA, the Chinese Football Association, the FIFA World Cup and other sporting events. Helios coordinated the marketing strategy for Major League Baseball’s first exhibition series in China this spring and managed sponsorship sales for the 2007 FIFA Women’s World Cup. The companies believe their alliance will be profitable in the aftermath of the Olympics, as many major sponsors of the games like Atlanta-based Coca-Cola Co. try to follow up on their Olympic efforts. “We are excited to be teaming up with Infront during this unique moment in the history of Chinese sports,” said Chris Renner, president of Helios China. Helios also has an office in London.For more information, visit www.heliospartners.com.
JVC Leases Atlanta Distribution Center
JVC Americas is a division of Wayne, N.J.-based JVC Americas Corp., which has its southeast service and sales centers in Lawrenceville. The American corporation is a wholly owned subsidiary of Victor Co. of Japan Ltd., in Yokohama, Japan. The site is one of 122 in the Atlanta area owned by industrial facility management firm ProLogis. The company’s other customers in Georgia include Home Depot Inc., LG Electronics Inc., Petco Animal Supplies Inc. and Subaru of America Inc. For more information go to www.jvc.com or www.prologis.com.
advertisement - story continues below
Delta Launches Flights to French, Honduran Cities
A nonstop flight from New York’s John F. Kennedy International Airport to Saint-Exupéry International Airport in Lyon, opened July 17. Lee Macenczak, Delta’s executive vice president for sales and marketing, said that the route is the first for the airline to France’s second-largest city. Delta announced July 22 a daily nonstop route from Hartsfield-Jackson Atlanta International Airport to Toncontin Airport in Tegucigalpa, Honduras, to start Dec. 18, pending Honduran government approval. Christophe Didier, Delta’s vice president of sales and government affairs for Latin America and the Caribbean, said that the airline is offering service to the Honduran capital because of successful flights to San Pedro Sula, Honduras, and Roatan, a coastal island. “Our flights to San Pedro Sula and Roatan have consistently performed well, and we are immensely optimistic to see Tegucigalpa become a great addition to our Honduras service,” he said. Delta is to expand its service to South America and the Caribbean with three other routes opening in December. A flight from New York to Buenos Aires, Argentina, is to open Dec. 18, with Argentinean government approval. A route from New York to Bonaire, an island in the Netherlands Antilles, is to launch two days later. Service from Atlanta to Santiago de los Caballeros, Dominican Republic, is also to start Dec. 20.For more information go to www.delta.com.
advertisement - story continues below
Atlanta Firm Partners with French Manufacturer to Produce Trial HIV Vaccine
GeoVax and Vivalis of Nantes, France, are developing the technology to mass-produce Modified Vaccinia Ankara, or MVA, a component of the HIV vaccine. The standard quantity MVA is a smallpox vaccine, which must be strengthened and produced in large quantities to be an effective piece of GeoVax’s HIV vaccine. Harriet Robinson, GeoVax’s senior vice president of research and development, said that the two companies have signed a letter of intent to continue developing the technology to produce the vaccine. “When we learned about the work of Vivalis…that might be able to be used to grow MVA, we contacted Vivalis and arranged with them to jointly conduct pilot studies on the growth of our MVA vaccine,” she said. “Our early production results have been very promising and have led to this (letter) for more formal development.” GeoVax is working with Emory University’s Vaccine Center, the National Institutes of Health in Bethesda, Md., and the Centers for Disease Control and Prevention to develop the vaccine. The medication goes into a new human trial phase this fall to continue testing its safety and effectiveness. For more information, go to www.geovax.com or www.vivalis.com.
|
||||||||
|
|
